Cargando…
Therapeutic Drug Monitoring of Ganciclovir in Cytomegalovirus-Infected Patients With Solid Organ Transplants and Its Correlation to Efficacy and Toxicity
Cytomegalovirus causes morbidity and mortality, especially in immunocompromised patients, and is treated with (val)ganciclovir. Therapeutic drug monitoring of ganciclovir is often performed; however, clinically established target trough levels corresponding to efficacy are lacking. In 2021, our clin...
Autores principales: | van der Wekken-Pas, Lena C., Totté, Joan, Lunel, Frans V., van Zuilen, Arjan, van Luin, Matthijs |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Therapeutic Drug Monitoring
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351899/ https://www.ncbi.nlm.nih.gov/pubmed/36730727 http://dx.doi.org/10.1097/FTD.0000000000001054 |
Ejemplares similares
-
Ganciclovir-resistant cytomegalovirus infection in renal transplantation
por: Vaz, Raquel, et al.
Publicado: (2014) -
Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
por: Vaziri, Siavash, et al.
Publicado: (2014) -
Ganciclovir therapeutic drug monitoring in transplant recipients
por: Märtson, Anne-Grete, et al.
Publicado: (2021) -
Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads
por: Märtson, Anne-Grete, et al.
Publicado: (2021) -
Ganciclovir/letermovir: Rebound Cytomegalovirus hepatitis, acquired resistance to ganciclovir and nephrotoxicity: case report
Publicado: (2020)